Alexion Optimistic Of Soliris' gMG Chances Despite Missing Ph III Target
Alexion Pharmaceuticals Inc. is reassessing its regulatory strategy after Phase III data for its warhorse Soliris in myasthenia gravis, a rare neuromuscular disease, missed statistical significance on the primary endpoint but the company hopes regulators will give the therapy the benefit of the doubt after more data are generated.
You may also be interested in...
Despite the early sell-off in life science stocks during last week’s American Society for Clinical Oncology (ASCO) conference, there were some very positive new developments for cancer patients. The only problem now is the question of who will pay for combination treatment regimens.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.